FindTrial
Sign In

A study to analyze the drug prescribing pattern with their side effect profile and effect of such treatment on Quality of Life among patients of acne vulgaris disease.

A prospective observational study for evaluating drug prescribing pattern and effect of treatment on Quality of Life in acne vulgaris patients attending dermatology outpatient in tertiary care centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/066802
Enrollment
204
Registered
2024-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Pramod Kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly enrolled Acne vulgaris patients seeking medical intervention for first time at AIIMS Rishikesh Age more than and equal to 15 years from either gender (male / female). Patient willing to undergo treatment and follow ups. Patient willing to give written informed consent to participate in study

Exclusion criteria

Exclusion criteria: Withdrawal of consent at any point after enrolment but before completion of follow-up. Pregnant and Lactating women. Patients diagnosed with systemic comorbidity/comorbidities requiring chronic treatment. Any dermatologic disease other than acne vulgaris. Patients with secondary causes of Acne like Drug induced Acne/acneiform eruptions.

Design outcomes

Primary

MeasureTime frame
1-To analyse drug prescribing pattern in acne vulgaris patients in relation to severity of acne and prevailing treatment guidelines. 2-To assess effect of treatment on quality of life in acne vulgaris patients, using Dermatology Life Quality Index (DLQI) and acne- specific Cardiff Acne Disability Index (CADI) at multiple time points of therapy.Timepoint: 1-At baseline visit 2-at 0(baseline), 3, and 6 months—

Secondary

MeasureTime frame
To assess effect of treatment on self-esteem in acne vulgaris patients, using Rosenberg Self-esteem Scale (RSES) at multiple time points of therapy.Timepoint: at 0(baseline), 3, and 6 months;To study the adverse event profile of treated acne vulgaris patients with active reporting of adverse events in patients treated with Retinoids.Timepoint: During OPD visits (3, and 6 months) and through telephonic calls.—

Countries

India

Contacts

Public ContactDr Gaurav Chikara

AIIMS Rishikesh

gaurav.phar@aiimsrishikesh.edu.in9587262037

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026